Phase 3 Clinical Trials With Primary Completion Dates in October 2016
This is a list of Phase 3 trials with primary completion dates in October 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ADHD | Alcobra Ltd. | 2016-10-01 | Phase 3 | NCT02477748 | The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD |
| AEZS | AEterna Zentaris Inc. | 2016-10-01 | Phase 3 | NCT02558829 | Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency |
| ALKS | Alkermes plc | 2016-10-01 | Phase 3 | NCT02218008 | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study |
| CYNA | Cynapsus Therapeutics Inc. | 2016-10-01 | Phase 3 | NCT02469090 | A Phase 3 Study to Examine the Efficacy, Safety and Tolerability of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease |
| EXEL | Exelixis, Inc. | 2016-10-01 | Phase 3 | NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib |
| FOLD | Amicus Therapeutics, Inc. | 2016-10-01 | Phase 3 | NCT01476163 | Physician Initiated Request for Migalastat in Individual Patients With Fabry Disease |
| INSM | Insmed, Inc. | 2016-10-01 | Phase 3 | NCT02344004 | Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone |
| ITEK | Inotek Pharmaceuticals Corporation | 2016-10-01 | Phase 3 | NCT02565173 | Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma |
| MNK | Mallinckrodt plc | 2016-10-01 | Phase 3 | NCT02321319 | Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients |
| MNK | Mallinckrodt plc | 2016-10-01 | Phase 3 | NCT02132195 | Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome |
| NEOT | Neothetics, Inc. | 2016-10-01 | Phase 3 | NCT02483533 | Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 |
| NURO | NeuroMetrix, Inc. | 2016-10-01 | Phase 3 | NCT02809846 | Quell Opioid Reduction and Pain Relief in Patients With Cancer |
| RDUS | Radius Health, Inc. | 2016-10-01 | Phase 3 | NCT01657162 | Twenty Four Month Extension Study of BA058-05-003 |
| TENX | Tenax Therapeutics, Inc. | 2016-10-01 | Phase 3 | NCT02025621 | Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass |
| TXMD | TherapeuticsMD, Inc. | 2016-10-01 | Phase 3 | NCT01942668 | A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms |
| VRX | Valeant Pharmaceuticals International, Inc. | 2016-10-01 | Phase 3 | NCT02462122 | Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis |
| VRX | Valeant Pharmaceuticals International, Inc. | 2016-10-01 | Phase 3 | NCT02462070 | Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis |